AbstractIn this report, a modified regimen based on IMpower 133 (carboplatin + etoposide + atezolizumab) was administered to a patient diagnosed with large cell neuroendocrine carcinoma (LCNEC) who was concurrently undergoing haemodialysis. Adverse events led to the discontinuation of carboplatin and etoposide after the first course. Nevertheless, the patient exhibited reduction in pulmonary nodule and adrenal metastasis while receiving atezolizumab, indicating its sustained efficacy for a duration of 7 months. To the best of our knowledge, this is the first documented case demonstrating successful treatment with atezolizumab in LCNEC patients undergoing haemodialysis. Atezolizumab can be administered safely in patients undergoing dialysis and is a promising therapeutic option for dialysis patients with LCNEC.

More from our Archive

• DOI: 10.1111/resp.14563 2023

  Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis

  Joy Zhao, Joseph Fares, Gautam George, Arlene Maheu, Giorgos Loizidis, Jesse Roman, Daniel Kramer, Michael Li, Ross Summer

• DOI: 10.1002/pul2.12270 2023

  Deletion of the <i>Npr3</i> gene increases severity of acute lung injury in obese mice

  Brianna D. Guarino, Christopher D. Dado, Ashok Kumar, Julie Braza, Elizabeth O. Harrington, James R. Klinger

• DOI: 10.36106/ijsr/1830060 2023

  THE PERCENT FRAGILITY INDEX

  Thomas F Heston

• DOI: 10.1111/crj.13672 2023

  Imaging and pathological characteristics, treatment, and prognosis of pulmonary sequestration—A retrospective study of 13 cases

  Xiangjin Liu, Rongqian Wu, Shenyu Zhu, Liang Gu, Zhixian Tang

• DOI: 10.1152/ajplung.00041.2023 2023

  Liraglutide pretreatment attenuates sepsis-induced acute lung injury

  Brandon Baer, Nathan D. Putz, Kyle Riedmann, Samantha Gonski, Jason Lin, Lorraine B. Ware, Shinji Toki, R. Stokes Peebles, Katherine N. Cahill, Julie A. Bastarache

• DOI: 10.2500/aap.2023.44.230022 2023

  Meteorological and environmental factors that impact pollen counts, allergenicity, and thresholds: A scoping review

  Donald R. Brake, Reena N. Yaman, Alyssa R. Camargo, Lisa A. Marks, Jacob T. Maddux, Sergei I. Ochkur, Matthew A. Rank

• DOI: 10.2500/aap.2023.44.230015 2023

  Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis

  Anju T. Peters, Martin Wagenmann, Jonathan A. Bernstein, Asif H. Khan, Scott Nash, Juby A. Jacob-Nara, Shahid Siddiqui, Paul J. Rowe, Yamo Deniz

• DOI: 10.1093/ejcts/ezad261 2023

  5-Year haemodynamic performance of three aortic bioprostheses. A randomized clinical trial

  Lourdes Montero Cruces, Manuel Carnero Alcázar, Daniel Pérez Camargo, Javier Cobiella Carnicer, Paula Campelos Fernández, Fernando José Reguillo Lacruz, Luis Carlos Maroto Castellanos

• DOI: 10.1002/rcr2.1193 2023

  Successful treatment with atezolizumab in a haemodialysis patient with large cell neuroendocrine carcinoma

  Ryosuke Imai, Atsushi Kitamura

• DOI: 10.1111/resp.14549 2023

  Proposed quality indicators and recommended standard reporting items in performance of <scp>EBUS</scp> bronchoscopy: An official <scp>World Association for Bronchology and Interventional Pulmonology Expert Panel</scp> consensus statement

  Daniel P. Steinfort, Matthew Evison, Ashleigh Witt, Georgios Tsaknis, Fayez Kheir, David Manners, Karan Madan, Calvin Sidhu, Alberto Fantin, Daniel A. Korevaar, Erik H. F. M. Van Der Heijden,